T45 Labs Closes Funding Round for Its Cardiovascular Companies

March 19, 2025—T45 Labs announced the close of its $25 million T45 Fund I. The fund will advance and fuel development and clinical research programs for the company’s portfolio of companies focused on accelerating the development of cardiovascular solutions.

T45, which is located in Santa Clara, California, manages each step of device development for its portfolio companies and collaborates with leading clinicians to develop, refine, and commercialize innovative devices, noted the press release.

According to the company, the funds have been committed and will continue to be directed toward advancing milestones for its cardiovascular portfolio, which includes the following:

• Advanced NanoTherapies, which is developing next-generation drug-coated balloons (DCB). Its SirPlux Duo DCB is a coronary and peripheral therapy designed to deliver sirolimus and paclitaxel simultaneously to inhibit cell growth. Findings from the ADVANCE-DCB first-in-human trial of the SirPlux Duo DCB were announced in November 2024.
• Vahaticor, which is focused on coronary microvascular dysfunction. Its A-Flux reducer system with SwiftCell technology treats complex coronary microvascular dysfunction to provide relief for patients with chronic symptoms. In November, the company announced the completion of a compassionate use study with the A-Flux reducer system.
• NuevoSono, which is an imaging company with intravascular ultrasound (IVUS) technology. Its Clear IVUS Choice offers near-OCT resolution with imaging depth and convenience of IVUS for coronary and peripheral anatomy visualization.
• ReCava, which is focused on reducing the clinical burden of congestive heart failure.